Verseon presented promising preclinical efficacy results on its plasma kallikrein inhibitors for the treatment of diabetic macular edema (DME) at the fifth annual Targeting Ocular Disorders conference in Boston last week, according to a company news release. The data suggest that Verseon’s novel drug candidates slow down the progression of DME and could be suitable for administration either via eye drops or oral dosing.
Dr. Timothy Shiau, Senior Scientist at Verseon, presented the latest results from an in vivo efficacy model that showed that certain plasma kallikrein inhibitors from Verseon reduce leakage into the retina and restore mean circulation times when dosed orally. Together with previously presented data confirming efficacy after infusion-pump dosing, these preclinical findings firmly establish that Verseon’s drug candidates successfully slow the progression of DME.
In addition, intraocular pharmacokinetic studies show that Verseon’s inhibitors reach good exposures in the relevant tissues of the eye when dosed as eye drops. Other candidates have good oral exposure and bioavailability. By developing its DME candidates for eye-drop or oral administration, Verseon aims to provide much-needed alternatives to the current standard of care comprising monthly injections into the eye and laser treatments.
“Plasma kallikrein inhibitors are promising candidates for slowing and potentially reversing DME,” Dr. Shiau said in a company news release. “We are excited about our recent results, which show that within our novel class of plasma kallikrein inhibitors, we have multiple candidates with excellent profiles for topical ophthalmic administration and others suitable for oral dosing.”
In addition to the diabetic macular edema, Verseon is also advancing programs in anticoagulation, hereditary angioedema, and oncology.